Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Labeling With Tiered Evidence Levels Eyed As Fix For Off-Label Promotion

This article was originally published in The Pink Sheet Daily

Executive Summary

Working group convened by Duke-Margolis Center for Health Policy lays out several policy proposals aimed at addressing current regulatory challenges with communication about unapproved uses of existing products.

Advertisement

Related Content

FDA Guidance On Health Care Economic Data Is Coming In 2015
FDA Promises More Off-label Guidances As Part Of First Amendment Harmonization

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS079119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel